Inflammaging and the Aging Immune Panel — What to Do With It

Drew, I've got a 71-year-old, hs-CRP of 2.9, neutrophil-to-lymphocyte ratio of 4.2, two lower respiratory infections in eighteen months, and a flu vaccine that apparently didn't take. Nothing hits a diagnostic threshold. Where do I start?

Before attributing anything to age — workup those infections properly. Severity, microbiology, imaging, quantitative immunoglobulins. You need to exclude a primary immunodeficiency before you call this a normal aging pattern.

Right, but once that's done and it's clear, what am I actually looking at biologically?

Two things happening simultaneously. The adaptive arm — T and B cells — is working from a narrowing repertoire because the thymus, which produces new naive T cells, has been involuting since puberty. She has less bench depth against novel antigens.

And the innate side — neutrophils, macrophages — what's happening there?

It shifts from resolving inflammation to sustaining it. Chronically activated without a clearing pathogen. That's inflammaging — persistent low-grade sterile inflammation — and her hs-CRP trend is a reasonable proxy for it, though not a diagnostic one.

How predictive is an NLR of 4.2 in practice?

Observational data only. Elevated NLR associates with cardiovascular events and all-cause mortality in older cohorts. It's a signal worth tracking, not a threshold that changes a prescription today.

What about the vaccine failure — can I actually measure why that happened?

Post-vaccination antibody titers can confirm non-response. If she's genuinely not seroconverting, the high-dose or adjuvanted influenza formulations — Fluzone High-Dose, FLUAD — are guideline-recommended by ACIP specifically for adults over 65, with trial evidence showing better immunogenicity.

That's actionable. What about the inflammation side — anything modifiable with real evidence?

Exercise is the strongest signal. Sustained aerobic and resistance training reduces inflammatory markers and preserves CD8 T-cell function in older adults. That's replicated human trial data, not mechanistic only.

Sleep and diet get mentioned constantly in this space — is that evidence or noise?

Chronic sleep restriction elevates IL-6 and CRP — that's controlled intervention data. Mediterranean dietary pattern associates with lower inflammaging markers — observational, so directional only. Neither has hard clinical endpoints yet.

What about the supplement aisle — senolytics, NAD precursors, rapamycin? Patients ask me constantly.

Mechanistic and early-phase data only. Dasatinib plus quercetin and navitoclax are senolytic candidates in trials; no clinical endpoint data I'd act on. Rapamycin extends lifespan in mice — no approved indication for immune aging in humans. Don't dose those.

So what does my patient actually leave with from this visit?

Exclusion workup first. Then switch her to adjuvanted influenza vaccine. Structure an exercise prescription — it's the one intervention with replicated human evidence for both arms of immune aging. And track the hs-CRP trend, not a single value.

And the single thing you'd want me to remember?

An older immune system isn't a weaker young one — it's a different one, with less repertoire depth and a chronically activated innate arm. That asymmetry explains the pattern. Everything else follows from it.